Found: 9
Select item for more details and to access through your institution.
Type 2 diabetes subgroups and response to glucose‐lowering therapy: Results from the EDICT and Qatar studies.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 9, p. 1810, doi. 10.1111/dom.14767
- By:
- Publication type:
- Article
Combination therapy with pioglitazone/exenatide improves beta‐cell function and produces superior glycaemic control compared with basal/bolus insulin in poorly controlled type 2 diabetes: A 3‐year follow‐up of the Qatar study.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 12, p. 2287, doi. 10.1111/dom.14153
- By:
- Publication type:
- Article
Pioglitazone prevents the increase in plasma ketone concentration associated with dapagliflozin in insulin‐treated T2DM patients: Results from the Qatar Study.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 3, p. 705, doi. 10.1111/dom.13546
- By:
- Publication type:
- Article
Insulin secretion predicts the response to therapy with exenatide plus pioglitazone, but not to basal/bolus insulin in poorly controlled T2DM patients: Results from the Qatar study.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 4, p. 1075, doi. 10.1111/dom.13189
- By:
- Publication type:
- Article
Efficacy of Exenatide Plus Pioglitazone Vs Basal/Bolus Insulin in T2DM Patients With Very High HbA1c.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Insulin resistance limits corneal nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control.
- Published in:
- Journal of Diabetes Investigation, 2021, v. 12, n. 11, p. 2002, doi. 10.1111/jdi.13582
- By:
- Publication type:
- Article
Painful diabetic neuropathy is associated with increased nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control.
- Published in:
- Journal of Diabetes Investigation, 2021, v. 12, n. 9, p. 1642, doi. 10.1111/jdi.13544
- By:
- Publication type:
- Article
Erratum. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. Diabetes Care 2017;40:325-331.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study.
- Published in:
- 2017
- By:
- Publication type:
- journal article